HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

South Korea · Delayed Price · Currency is KRW

2,105.00

-15.00 (-0.71%)

Sep 1, 2026, 3:30 PM KST

HLB Therapeutics Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	64,447	69,561	54,932	52,591	42,403	43,586
Revenue Growth	5.25%	26.63%	4.45%	24.03%	-2.72%	1.53%
Gross Profit	4,021	10,032	9,979	7,184	8,721	5,007
Operating Income	-9,302	-3,582	-7,624	-8,869	-7,507	-11,087
Net Income	-18,022	-9,227	-22,793	-2,302	-11,354	-17,197
Earnings Per Share	-204.45	-104.74	-270.00	-28.15	-158.92	-266.85
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	13,235	45,998	37,773	32,353	64,012	100,567
Total Debt	40,436	40,550	23,353	10,022	52,131	51,126
Net Cash (Debt)	-27,201	5,448	14,420	22,330	11,881	49,441
Net Cash Growth	-	-62.22%	-35.42%	87.95%	-75.97%	219.98%
Net Cash Per Share	-308.59	61.84	170.82	273.07	166.30	767.17

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-3,887	-8,178	1,288	3,327	-8,809	-11,268
Capital Expenditures	-841.51	-1,285	-636.97	-301.76	-3,396	-822.87
Free Cash Flow	-4,728	-9,463	650.79	3,025	-12,204	-12,091
Free Cash Flow Growth	-	-	-78.49%	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	6.24%	14.42%	18.17%	13.66%	20.57%	11.49%
Operating Margin	-14.43%	-5.15%	-13.88%	-16.86%	-17.70%	-25.44%
Pretax Margin	-31.08%	-15.94%	-41.74%	-5.64%	-27.29%	-40.76%
Profit Margin	-27.96%	-13.26%	-41.49%	-4.38%	-26.78%	-39.45%
FCF Margin	-7.34%	-13.60%	1.19%	5.75%	-28.78%	-27.74%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 1, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	-	236.63	236.63	236.63	236.63	236.63
P/FCF Ratio	-	-	1435.95	109.54	-	-
PS Ratio	3.05	3.62	17.01	6.30	8.61	8.69